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ABSTRACT 
An autoantigen piezoelectric sensor to quantify specific circulating autoantibodies in 
human serum is developed. The sensor consisted on a quartz crystal microbalance with 
dissipation monitoring (QCM-D) where TRIM21 and TROVE2 autoantigens were covalently 
immobilized, allowing the selective determination of autoantibodies for diagnosis and 
prognosis of Systemic Lupus Erythematosus (SLE). The sensitivity of the biosensor, 
measured as IC50 value, was 1.51 U/mL and 0.32 U/mL, for anti-TRIM21 and anti-TROVE2 
circulating autoantibodies, respectively. The sensor is also able to establish a structural 
interaction fingerprint pattern or profile of circulating autoantibodies, what allows scoring 
accurately SLE patients. Furthermore, a statistical association of global disease activity with 
TRIM21-TROVE2 interaction was found (n = 130 lupic patient samples, p-value = 0.0413). 
The performances of the biosensor were compared with standard ELISA and multiplex DVD-
array high-throughput screening assays, corroborating the viability of piezoelectric biosensor 
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as a cost-effective in vitro assay for the early detection, monitoring or treatment of rare 
diseases. 
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1. INTRODUCTION 
Systemic lupus erythematosus is a chronic inflammatory autoimmune disease (Chan et al., 
2012) that adversely affects nearly every organ (skin, heart, lungs and intestines) of the 
human body, what makes it a harmful and high morbi-mortality illness 
(http://www.lupus.org/). SLE is generally considered the model systemic autoimmune 
disease, affecting 40-50 people per 100,000 with a 9:1 female-to-male ratio (WHO, 2006). 
Furthermore, both the genetic and non-genetic components of ethnicity influence in the 
expression and outcome of SLE. 
The symptoms developed by SLE patients vary considerably from person to person and 
are quite similar to other common rare diseases what make the diagnosis of lupus difficult 
(Buhl et al., 2009). Therefore, the Systemic Lupus Collaborating Clinics (SLICC) employs 
stringent methodology requirements as criteria for SLE classification. As far as the diagnosis 
of SLE is concerned, the patient must satisfy at least 4 out of 17 SLICC requirements, 
including at least one clinical and one immunological criterion.  
One of the main disadvantages of the clinical practice to diagnose SLE is that many 
indexes are subjective, because the scoring relies on reporting the symptoms by the patients 
rather than objective documentation and quantitative analytical results. This makes difficult 
to differentiate patients with multiple mild manifestations from those with severe symptoms. 
As no single criterion can describe the status for all the SLE patients, a Systemic Lupus 
Erythematosus Disease Activity Index (SLEDAI) is also used for diagnosis. The index is 
used by the physician to evaluate the patient records and as a measure of global disease 
activity in the clinic. The interpretation of the index has been shown to be reliable and valid. 
However, SLEDAI is focused on new or recurrent manifestations and fails to capture on-
going activity. 
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According to several studies, the determination of specific autoantibodies facilitates the 
diagnosis of lupus (Rubin et al., 2014). These autoantibodies have been a cornerstone in 
understanding pathogenesis, supporting the management and treatment of SLE (Rubin and 
Konstantinov, 2016). Autoantibodies are typically present many years before the diagnosis of 
the disease and their presence tends to follow a predictable course, with a progressive 
accumulation before the onset of SLE, while patients are still asymptomatic (Eriksson et al., 
2011).  
Patients with autoimmune rheumatic diseases, such as SLE, have multitude of circulating 
autoantibodies against intracellular autoantigens (Biesen et al., 2016; Fritsch et al., 2006; Hu, 
et al., 2014; Defendenti et al., 2011). The primary autoantigens are U1-ribonucleoproteins, 
Sm, topoisomerase I, Jo-1, and Ro52/TRIM21, Ro60/TROVE2, and La (Fritsch et al., 2006). 
However, not all of the autoantibodies are specific for a particular autoantigen but they are 
useful biomarkers to help ruling in or out systemic autoimmune rheumatic diseases. Among 
the most common autoantibodies are those that target the autoantigens TRIM21 and 
TROVE2 (Al kindi et al., 2016).  
The measurements to diagnose SLE consider the concentration of anti-Ro/SSA 
autoantibodies against the entire Ro complex, but few bioassays tests are capable to 
determinate the concentration of the specific autoantibodies to their two main components 
(TRIM21 and TROVE2). In fact, both autoantigens are major targets of the immune system 
in patients suffering with SLE and they are determined during the course of organ-specific 
autoimmune diseases. Therefore, the clinical prognostic and therapeutic utility of determining 
anti-TRIM21/TROVE2 circulating autoantibodies is of great interest (Menendez et al., 2013). 
Regarding the quantitative methods for diagnosis, several assays have been developed for 
the determination of autoantibodies including, ELISA, line blot immunoassays, multiplex 
flow immunoassay and protein arrays (Infantino et al., 2013). Key advantages of these assays 
are its ease of use, flexibility, and low cost. However, the main limitation is concerned with 
the low sensitivity what limits the determination of the extremely low concentrations of 
circulating antibodies in serum. Therefore, the development of high sensitive biosensors is of 
great interest to determine autoantibodies at very low concentrations.  
Quartz Crystal Microbalance (QCM) technique has been used extensively in biosensing 
(Cheng et al., 2011), because its good performance such as accuracy, stable oscillators and 
capability for label-free detecting subnanogram mass changes in real-time. It shows high 
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temperature dependence and lack multiplexing and high-throughput capabilities. (Pesquero et 
al., 2010). Nevertheless, the high sensitivity and low detection limits of QCM sensors offer 
excellent advantages over traditional sensing techniques. In particular, QCM-D (Quartz 
Crystal Microbalances with Dissipation) displays unique properties of sensing mass as well 
as viscoelastic effects together in single set of measurements (more than 200 data points per 
second), giving an innovative perspective in the domain of sensitivity range. In addition, 
QCM-D is attractive due to sensor response in the form of variations in the dissipation factor 
(ΔD) that is related to the viscoelasticity, which in turn is often associated to structural 
changes of the film adhering on the QCM-D transducer. This adds complementary 
information in relation with structural interactions between probe and target. In this sense, 
Hussain et al. (2016) reported the good performances of QCM-D, beating the standard 
coagulometer in terms of sensitivity range and information for hemostasis of human plasma.  
The main goal of this research is therefore to develop high sensitive QCM-D based label-
free biosensors for monitoring anti-TRIM21 and anti-TROVE2 circulating autoantibodies in 
a dynamic context. This would allow setting a characteristic interaction fingerprint pattern as 
consequence of the associated structural changes of the film during the molecular 
autoantigen-autoantibody recognition event. To the best of our knowledge, there are no 
reports of biosensing anti-TRIM21 and anti-TROVE2 circulating autoantibodies in human 
serum at low concentrations to diagnose and predict SLE disease. The new biosensing 
approach was used to test a pool of positive and negative sera, establishing a specific 
interaction pattern for SLE patients and healthy subjects.  Furthermore, the performance of 
label-free biosensor was compared with the results displayed by standard ELISA plate and 
multiplex DVD-array high-throughput screening assays, showing the high potential of the 
QCM-D biosensing approach to diagnose and predict SLE. 
 
2. MATERIALS AND METHODS 
2.1. Patients and Samples 
A total of 145 SLE patients and 8 healthy individuals provided full-informed written 
consent for this observational study. The approvals were obtained from the Biomedical 
Research Ethics Committee of the University and Polytechnic La Fe Hospital (Valencia, 
Spain). All patients agreed to take part in the study and satisfy the SLICC-ACR2012 
classification criteria (Petri et al., 2012). The patients underwent complete medical 
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examination upon enrolment, and in the clinical visit lupus disease activity was assessed 
using the SLE Disease Activity Index (SLEDAI) (Gladman et al., 1992). Blood samples were 
collected by venipuncture of forearm veins from patients and healthy controls. Blood was 
collected in Vacutainer tubes containing EDTA, centrifuged for 15 minutes at 1,500 rpm, 
aliquoted (0.5 mL) into cryo tubes, and immediately frozen at -80 °C in La Fe Biobank. The 
samples were managed by the La Fe Biobank, PT13/0010/0026, following the criteria and 
ethical and legal requirements established by the 14/2007 Biomedical Research Law and 
1716/2011 Royal Decree of Biobank Activity Rules. 
A pool of fifty anti–Ro+ SLE patients’ sera (SLE IgG) was purified by affinity 
chromatography (GE Healthcare, HiTrapTM protein G HP). The purified IgGs were used as 
autoantibodies standards. In the same manner, a pool of eight healthy subjects’ sera (healthy 
IgG) was purified by affinity chromatography. The concentration of anti-TRIM21 and anti-
TROVE2 autoantibodies of each patient was quantified by means of a human anti-SSA(Ro-
52) ELISA kit  and a IgG anti-SSA 60 kDa ELISA kit (Dia Pro Diagnostic Bioprobes), 
respectively. The optical density of each well was measured using a microplate reader 
(Wallac, Victor 1420 multilabel counter) at 450 nm.  
The screening assay was performed on a regular DVD. Briefly, the polycarbonate surface 
of the DVD was coated with the autoantigens (TRIM21 and TROVE2) in microarray format 
(see supplementary material). The samples (sera) was directly dispensed onto the array (25 
µL) and incubated at 37 ºC for 15 min. Then, the disc was washed with PBST and rinsed with 
deionized water. The immunoreaction was detected and amplified using anti-human IgGs 
labelled with gold and the silver enhancement solutions, respectively. A detailed description 
of the assay protocol is included in the supplementary material. The results of the DVD 
assays were analysed as previously described (Morais et al., 2010).   
 
2.2. Quartz crystal microbalance with dissipation monitoring (QCM-D) 
QCM-D measurements were carried out using commercially available gold Q-sense 
sensors (5 MHz, QSX 301, Biolin Scientific). The variation of frequency and dissipation was 
monitored using a Q-Sense E1 device equipped with a liquid flow cell setup. All experiments 
were carried out in 10 mM phosphate buffer saline (PBS), pH 7.4 at a flow rate of 50 µL/min 
at 25 °C. 
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The piezoelectric quartz crystal chip was first cleaned by UV irradiation (254 nm) for 10 
min. Then, the chip was immersed in a solution of 5:1:1 of milli-Q water, ammonia 25% and 
H2O2 30% at 75 °C for 5 min. Next, the chip was rinsed with milli-Q water, and blown dry 
with nitrogen. Finally, the chip was treated with UV again during 10 min. Self-assembled 
monolayer (SAM) was performed by immersing the quartz crystal in 10 mM MPA solution 
(3-mercaptopropionic acid) overnight and then activated with 46 mM of EDC -N-ethyl-N’-
(3-dimethylaminopropyl) carbodiimide, NHS (N-hydroxysuccinimide) 98% for 1 h.  
After activation of SAM, the chip was treated with 5 mM carbohydrazide 98 % for 1 h. 
Next, 100 µL of the buffered  autoantigen  solution (33 mg/L of TRIM21 (recombinant 
human RO-52/SS-A expressed in E. Coli, Sigma-Aldrich) or TROVE2 (recombinant human 
RO-60/SS-A expressed in E. Coli, long isoform, ProSpec) was dispensed over the sensor and 
incubated for 1 hat room temperature. The crosslinked residues were blocked by immersing 
the god sensor in a 1 M ethanolamine-HCl ≥ 98% solution for 1 h and next, in a blocking 
buffer solution, containing 1 mM ethylenediaminetetraacetic acid (Riser), 0.25% bovine 
serum albumin (BSA, Sigma-Aldrich, ≥98% agarose gel electrophoresis), and 0.05% Tween-
20 (Scharlau, synthesis grade) (Hong et al., 2009). Next, the chip was rinsed with milli-Q 
water and blown dry with nitrogen. The sensing chips were characterized by Static Water 
Contact Angle (SCA), Polarization Modulation Infrared Reflection Absorption Spectroscopy 
(PM-IRRAS) and X-ray Photoelectron Spectroscopy (XPS), as described in Supplementary 
Material. 
The sensing chip was placed into the flow module with the side coated with the 
autoantigen facing up. The system temperature was adjusted to 25 °C at a flow rate of 50 
µL/min. Then, PBS was circulated on the surface sensor until stabilization. The resonance 
frequency was monitored until a steady baseline was obtained (f0). Then, 1.0 mL of 
autoantibodies standards at different concentrations (0.02-3.0 U/mL for anti-TRIM21  and 
0.01-1.5 U/mL for anti-TROVE2 ) were recirculated into the system for 1 h to reach the 
steady state. Next, PBS buffer was injected into the flow to remove bulk effects on 
viscoelastic properties of sensor chip. When the resonance frequency reached a stable value, 
another steady state resonant frequency was taken (f1). The frequency shifts (Δf = f0–f1) 
induced by the protein-autoantibody binding was the difference between the value displayed 
before reaction (f0) and the final value (f1). The frequency shifts were correlated precisely to 
the change of surface concentration using the Sauerbrey equation (17.7/n ng cm
-2
 Hz
-1
, n is 
the harmonic number). The mean value was the average of two replicates. The dose-curve 
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was plotted according to the relationship between surface concentrations and autoantibody 
concentrations. BSA and active human crystallisable region (Fc, Abcam, active human IgG 
FC fragment) were used as negative controls. 
The biosensor was regenerated, accomplishing a desorption step, using 0.1 M glycine/HCl, 
pH 2.5 at a flow rate of 50 µL/min at 25 °C.  
 
2.3. Statistical method 
Data are presented as the mean (standard deviation) and median (1st, 3rd quartile) in the 
case of continuous variables and as relative and absolute frequencies in the case of 
categorical variables. Differences in continuous variables among groups were assessed using 
Wilcoxon rank-sum test. Relationships among different variables were evaluated using linear 
regression, ordinal regression and logistic regression as appropriate. Differences were 
considered significant at p-values less than 0.05. All statistical analyses and graphs were 
performed using the R software (The R Project for Statistical Computing, https://www.r-
project.org/). 
 
3. RESULTS 
3.1. QCM-D-based TRIM21 biosensor 
Although both TRIM21 and TROVE2 take part in the Ro/SSA RNP complex, the 
expression level of the TRIM21 protein is higher than that of TROVE2. For this reason, the 
QCM-D-based biosensor was optimized first for the detection of circulating autoantibodies to 
TRIM21 antigen. In this study, a direct immunoassay was developed where the simple 
binding between the TRIM21 antigen and its respective autoantibody was label-free detected 
by the QCM-D biosensor. The sensing surface consisted in gold-coated QCM-D quartz 
crystals with TRIM21 covalently immobilized via a SAM. As Figure 1a shows, recombinant 
human TRIM21 protein was immobilized onto the gold chip using 3-mercaptopropionic acid 
as a monolayer precursor and subsequent covalent EDC coupling (surface concentration 267 
ng/cm
2
, coverage percentage close to 100%).  
The immobilization process of TRIM21 and TROVE2 on the gold surface was 
characterized by XPS, PM-IRRAS, DPI and SCA (Figure 1). After the addition of MPA acid 
(Figure 1b), the sulphur percentage measured by XPS increased (0-4.69%), also increasing 
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the SCA (56.9º-69.01º). The EDC/NHS reaction and the addition of carbohydrazide induced 
an increase of the nitrogen percentage (0-3.53%), decreasing consequently the SCA (69.01º-
55.8º). Finally, the immobilization of the TRIM21 protein and the blockage process rendered 
a clear increase of carbon (55.60-63.70%) and nitrogen (3.53-12.30%) percentages, as 
expected after these immobilisation steps. The SCA remained virtually constant (55.80º-
56.70º). 
PM–IRRAS spectra of the fabricated SAM was performed in the 4,000-800 cm
-1
 spectral 
range (Figure 1c). The spectral bands revealed the presence of proteins, and the homogeneity 
and high-structural order in the gold surface was demonstrated by the high-defined peaks. 
Finally, the C-terminal-oriented immobilization of TRIM21 was monitored by DPI (Figure 
1d). The protein orientation depends on the surface coverage. First, the protein was anchored 
in a vertical orientation (thickness/molecule about 14 nm/molecule). However, as the surface 
coverage increases, DPI monitored a restructuring of the monolayer, in which the TRIM21 
molecule orientation changed from a vertical (14 nm/molecule) towards a flat-on manner 
orientation (6 nm/molecule). The TRIM21 theoretical dimensions confirm the process of the 
protein deposition, about 21.4×7.4×5.6 nm. Hence, the surface characterization corroborated 
the formation of a hydrophilic SAM of TRIM21 with high structural order and surface 
homogeneity.  
The piezoelectric biosensor operates on the principle that a change in mass, resulting from 
the interaction between the autoantibody (biomarker) and its respective autoantigen 
(immobilized probe), can be directly determined (Figure 2a). The dependence of the apparent 
mass change on the bulk concentration of anti-TRIM21 autoantibody standards from SLE 
patients (0.02-3.0 U/mL, see Materials and Methods section) was stablished. As Figure 2b 
shows, the surface concentration of the antigenic complex increases as the bulk concentration 
of SLE IgG standards increases. The signals were fitted to the general Hill equation 
(R
2
=0.99) (Figure 2b). Using this fitting, the calculated limit of detection (LOD) of the assay 
for anti-TRIM21 autoantibodies was 0.01 U/mL. This LOD was established according to the 
concentration given by the interpolation of the blank signal (0 ng/cm
2
) plus 3 times the  
standard deviation (SD, 8.85 ng/cm
2
). The limit of quantification (LOQ), calculated as the 
concentration given by the interpolation of the blank signal plus ten times the SD of the blank 
measurements, was 0.04 U/mL. The assay sensitivity calculated from the half-maximal 
inhibitory concentration (IC50), was 1.51 U/mL, with a dynamic range (DR, defined 
presenting the transition from 20% to 80% maximal signal) between 0.32 and 7.17 U/mL. 
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The reproducibility of the measurements was within the range 5 to 10%. Herein, it is 
important to emphasize that the developed biosensor is able to determine TRIM21 within a 
low concentration range, discriminating well the negative control (BSA, signal equal to zero). 
In comparison to the ELISA plate format (IC50 117 U/mL and LOD 1.2 U/mL), the 
developed QCM-D biosensor was 120 times more sensitive and alleviated the need for 
labelled secondary antibodies as well. 
In order to discriminate between SLE and healthy subjects, the recognition event which 
involves only the antibody standards from healthy donors was also studied (Figure 2b). As in 
the previous study, the evolution of the surface concentration of the antigenic complex was 
studied according to the bulk concentration of healthy IgG standards (control IgGs). The 
obtained response was also evaluated via the general Hill equation (R
2
= 0.95). However, a 
substantial change in the antibody selectivity is observed, depending on the standard origin, 
which shows that anti-TRIM21 autoantibodies from patients and healthy subjects have 
different affinity (maximum surface concentration 766 ng/cm
2
 for SLE standard and 110 
ng/cm
2
 for healthy standard). 
The reason why the developed QCM-D-based TRIM21 biosensor showed non-zero signal 
for health subjects (Figure 2c) is probably due to the capability of the PRY-SPRY domain to 
recognize Fc (McEwan et al., 2013). The cut-off for scoring patients with SLE was stablished 
at 110 ng cm
-2
, corresponding to a concentration of TRIM21 of 0.2 U/mL.  
The accuracy of the analytical methods generally decreases by the presence of different 
circulating endogenous factors. A commonly used strategy to remove or decrease the matrix 
effect is the sample dilution, which works well with immunoassays exhibiting very high 
sensitivity (Ramakrishna and Mehan, 1993). Thus, a fit-for-purpose assessment was 
performed for the analysis of serum samples in order to demonstrate the applicability of the 
piezoimmunosensor in the clinical practice. Figure 2c shows how the signal due to non-
specific interactions of the matrix (sera pool without immunoglobulins G) of SLE patients 
(yellow bars) and healthy subjects (blue bars) decreases as the serum is diluted. The matrix 
effect of the QCM-D-based TRIM21 biosensor is below the cut-off value for 1:100 diluted 
serum samples (80 ng cm
-2
 from SLE patients and 107 ng cm
-2
 from healthy subjects).   
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3.2. QCM-D-based TROVE2 biosensor 
Both TRIM21 and TROVE2 proteins are part of the Ro/SSA RNP complex, so the 
determination of the concentration of anti-TROVE2 autoantibodies is also of great interest. 
Recombinant human TROVE2 protein was immobilized onto a gold QCM-D sensor via 3-
mercaptopropionic acid as a monolayer precursor and covalent EDC/NHS coupling (surface 
concentration 194 ng/cm
2
, coverage percentage 91%). As for TRIM21, the immobilization 
process was characterized systematically with XPS, SCA and DPI measurements. As is 
shown in Figure 1, the immobilization of TROVE2 was correctly completed. The 
immobilization step induced a clear increase of the carbon (11.1%-53.8%) and nitrogen (0%-
9.3%) percentage, whereas the SCA remained virtually constant (56.9º-56.7º) as is depicted 
in Figure 1b. 
C-terminal-oriented immobilization of TROVE2 was monitored by DPI. Figure 1e shows 
how the protein orientation depends on the surface coverage. Firstly, the protein is deposited 
in a vertical orientation (thickness/molecule = 9 nm/molecule). However, as surface coverage 
increases and therefore, steric effects are higher, DPI monitors a change in the TROVE2 
immobilization from a vertical orientation towards a flat-on manner, 9 to 3 nm/molecule. The 
measured TROVE2 dimensions are 8.5×5.5×3 nm (Stein et al., 2005). Therefore, theoretical 
data confirm the proposed orientation. As in the previous case, we generate a hydrophilic 
SAM with high structural order and surface homogeneity. 
Figure 2b shows how the surface concentration of the antigenic complex detected by the 
developed piezoimmunosensor increases as the concentration of SLE IgG standard also 
upturns (0.01-1.5 U/mL). This progression can be described using the general Hill equation 
(R
2
=0.99), reaching a LOD of 0.005 U/mL. This LOD is 400 times more sensitive than the 
commercial ELISA test (LOD 2.0 U/mL). On the other hand, the LOQ was 0.019 U/mL and 
the IC50 0.32 U/mL, with a DR from 0.07 to 1.46 U/mL. The negative binding control gave 
early zero signal for all the range of concentrations employed, corroborating the selectivity of 
the biosensor and the absence of unspecific interactions. In contrast to the case of TRIM21, 
the response of the developed biosensor for TROVE2 is only due to epitope-paratope specific 
interactions since the piezoelectric signal was zero when active human antibody Fc fragment 
was used as negative binding control. 
In order to discriminate between SLE and healthy subjects (Figure 2b) the recognition 
involving healthy IgG standards was also studied. The obtained piezoelectric response was 
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adjusted with a nonlinear Hill model (R
2
 = 0.99), showing a substantial change in the 
autoantibody affinity (maximum surface concentration 440 ng/cm
2
 for SLE IgG standards 
and 150 ng/cm
2
 for healthy IgG standards). The anti-TROVE2 autoantibodies have different 
paratopes depending on the standard origin. Hence, the established cut-off value for this 
biosensor was 150 ng/cm
2
 (110 ng/cm
2
 for the QCM-D-based TRIM21 biosensor). This value 
allows identifying easily between a pathologic (> 0.16 U/mL) and normal status (< 0.16 
U/mL). In order to unify sensing criteria, the cut-off value for TRIM21 and TROVE2 
piezoimmunosensors should be set at 150 ng/cm
2
. 
Figure 2c shows how the piezoelectric signal due to non-specific interactions of the matrix 
(sera pool without immunoglobulins G) of SLE patients (black bars) and healthy subjects 
(brown bars) decreases as the dilution of the serum increased. In both cases, the matrix effect 
was removed by diluting the serum 100 times (5.9 ng/cm
2
). Hence, the developed QCM-D-
based TROVE2 biosensor determine the concentration of anti-TROVE2 autoantibodies in a 
1:100 serum dilution. In conclusion, TRIM21 and TROVE2 piezoimmunosensors quantify 
with good sensitivity anti-TRIM21 and anti-TROVE2 autoantibodies in human serum in a 
label-free way without previous purification steps. 
Reusability is one of the main issues found in biosensing. To estimate the 
piezoimmunosensor mean life, repeated analyses of anti-TRIM21 standards (1.5 U/mL) were 
carried out. After the regeneration step, the sensor chip was considered useful while the 
piezoelectric signal remained above 90% of the initial value. In a continuous work, the piezo 
signal remained constant for at least 30 assay cycles. More than 30 assay cycles resulted in a 
significant loss of the piezo signal. Therefore, the useful life of the sensor was established as 
30 assay cycles. Considering the mean life of the piezoimmunosensors, the tiny amount of 
immobilized target required, and the non-need of using auxiliary immunoreagents for 
detection, a price of 2€ per assay is estimated. However, the price can be significantly 
reduced when the sensors were manufactured in mass.  
 
3.3. Interaction fingerprint pattern 
The main advantage of QCM-D compared with the conventional QCM, is the possibility 
of measuring both changes in resonant frequency (f) and, the energy loss or dissipation (D) of 
the system. In this manner, both signals were measured and the -∂f/∂D function was 
calculated, providing the reaction path of the monitored interaction. This path is specific of 
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the studied biochemical system, which could allow SLE patients and healthy subjects to be 
scored. In this way, the developed piezoimmunosensors can simultaneously determine 
circulating autoantibodies concentration working as a traditional sensor and additionally 
given information about the interaction fingerprint pattern that is related with the structural 
interaction profile.  
As is depicted in Figure 2, the autoantibodies from patients and control subjects have a 
different recognition mechanism of the recombinant human TRIM21. In view of that, using 
the developed biosensor, the interaction fingerprint pattern was established from the -∂f/∂D 
function. For that, 80,000 data points with three coordinates (time, f, D) was measured at real 
time for each biomarker concentration (0.06-8.0 U/mL) during 3,000 s. Figure 3 shows how 
the TRIM21-IgG reaction path is different for SLE patients and healthy subjects. Thus, in 
SLE patients, the -∂f/∂D function is a peak-shape function whose peak intensity does not 
depend on the bulk concentration of anti-TRIM21 autoantibodies, 19 Hz at 1,000 s. However, 
the -∂f/∂D function from healthy subjects has the same characteristics than from SLE IgGs, 
but with a constant peak intensity about 9 Hz at 600 s (8.8 Hz at 1,000 s), which is 2.1 times 
lower than in the patient group. Consequently, an interaction fingerprint pattern was 
established for the fast identification of anti-TRIM21 circulating autoantibodies from SLE 
patients in human serum samples. This pattern represents the structural interaction profile of 
the sick antigenic complex and could be a selection criterion for further screening strategies. 
Moreover, it can be applied to detect false positive (-∂f/∂D < 10 Hz at 1,000 s) and to 
improve the true positive rate (-∂f/∂D = 19 Hz at 1,000 s) of the developed ultrasensitive 
immunosensor. The -∂f/∂D function allows taking advantage of the huge information offered 
by the protein conformational dynamics. 
Following this step, the TROVE2-antibody interaction fingerprint pattern was also 
calculated. Figure 3 shows how this pattern is not such a specific pattern of SLE. The reaction 
path of this interaction was found to be similar for SLE patients and control subjects, and 
independent on the bulk concentration of anti-TROVE2 standards (0.2-27 U/mL). It is a 
peak-shape function with a maximum value of 11 Hz at 1,000 and of 9 Hz at 300 s (8.6 Hz at 
1,000 s) for autoantibodies from SLE patients and healthy subjects, respectively. Both values 
are very similar and consequently, it is not possible to differentiate easily between SLE 
patients and healthy subjects through this pattern. The only feasible pattern for characterizing 
the SLE patient group is the TRIM21-antibody interaction fingerprint. 
 
 
13 
 
3.4. Biostatistics 
As Hanly et al. reported (2010), there is a significant association between elevated global 
SLE disease activity index SLEDAI (which is a tool used to quantify the symptoms of 
patients with SLE) and the concentration of anti-Ro circulating autoantibodies. Consequently, 
an ordinal regression model (n = 130 real samples from SLE patients) was used to evaluate 
the association of global SLE disease activity with the concentration of anti-TRIM21 and 
anti-TROVE2 and the interaction between both.  
No statistical association of activity index with the anti-TRIM21 and anti-TROVE2 
concentration was found (p-value = 0.335 and 0.109, respectively). However, there was a 
statistical effect considering the TRIM21-TROVE2 interaction (p-value = 0.0413). Thus, the 
simultaneous measurement of both autoantibodies may become an important part of the 
overall assessment of SLE patients in clinical practice. For the characterization of SLE 
patients, it is very important to determine simultaneously the individual concentration of anti-
TRIM21 and anti-TROVE2 autoantibodies in serum (quantification of the symptoms of 
patients with SLE), as well as to establish an interaction fingerprint pattern (SLE diagnosis). .  
 
3.5. Screening assay 
A duplex immunoassay would have the ability to detect both biomarkers (anti-TRIM21 
and anti-TROVE2) concurrently in a single biological sample, along with negative and 
positive binding controls. As a first approximation, a microarray detection system based on 
the compact disc technology (Morais et al., 2010) was used. A non-competitive sandwich 
immunoassay for the simultaneous determination of circulating anti-TRIM21 and anti-
TROVE2 immunoglobulins was employed, as a proof of concept (Figure 4a).  
Under the optimized conditions (see Supplementary Material), the sensitivity of the 
assays, measured as IC50, the limit of detection (LOD), and dynamic range were determined. 
The calibration curves obtained for the simultaneous determination of the multiplexed 
immunoassays are shown in Figure 4b. The standard curve for the anti-TRIM21 biomarker 
was fitted using the four-parameter Gompertz equation (R
2
 = 0.997), because the diffusion of 
reactants greatly influence the assay response at these experimental conditions (Avella-Oliver 
et al., 2013), reaching a LOD, of  11 U/mL and a IC50 value of 96 U/mL. On the other hand, 
for the anti-TROVE2 biomarker, the calibration curve was fitted from the four-parameters 
Hill equation (R
2
 = 0.995), reaching a of  LOD of 58 U/mL and a  IC50 of 228 U/mL. Herein, 
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it is important to emphasize that cross-reactivity was not detected at these experimental 
conditions. The relative standard deviation values along the whole calibration curve were 
below 10%. It is also worth mentioning that multiplexed immunoassay reached similar 
sensitivity (IC50) of ELISA plate format (IC50 117 and 42 U/mL for anti-TRIM21 and 
antiTROVE2 in ELISA assay, respectively), and it was much less sensitive than QCM-D-
based label-free biosensor (IC50 1.51 and 0.32 U/mL for anti-TRIM21 and antiTROVE2 in 
ELISA assay, respectively). 
4. CONCLUSION 
The main advantage of using QCM-D biosensors for Systemic Lupus Erythematosus 
diagnosis is three fold. First, the ultra-sensitive biosensing approach allows the determination 
of circulating anti-TRIM21 and anti-TROVE2 autoantibodies in human serum at low U/mL 
levels. In comparison to current used analytical methodologies, the sensitivity reached by 
QCM-D biosensors is two orders of magnitude higher than ELISA tests, offering the 
possibility to detect the disease much earlier than the symptoms arise, since autoantibodies 
are typically present many years before the diagnosis of SLE, while patients are still 
asymptomatic. Secondly, using a novel -∂f/∂D function the QCM-D-based biosensor 
provided accurate real time information about molecular interaction fingerprint pattern or 
profile. This complementary information could be used in the clinical practice to characterize 
subjects with systemic autoimmune disease, providing the specific fingerprint of the 
TRIM21-autoantibody binding pattern. 
The analysis of the data of 130 patients gave statistical association of global SLE disease 
activity with the TRIM21-TROVE2 interaction. Consequently, the full characterization of the 
SLE patient group might be done by measuring simultaneously the TRIM21-antibody 
binding fingerprint pattern and the concentration of circulating anti-TRIM21 and anti-
TROVE2 autoantibodies. Indeed, the developed biosensors allow the simultaneous diagnosis 
(TRIM21-antibody binding fingerprint pattern) and prognosis (determination of anti-TRIM21 
and anti-TROVE2 autoantibodies) of SLE patients. The measurement of both circulating 
autoantibodies may become an important part of the overall management and treatment of 
SLE. Third, the QCM-D biosensors allow for a label free detection of circulating 
autoantibodies molecules, offering new insights in the molecular recognition process by 
exploring the kinetics and thermodynamics of specific interactions. 
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The developed immunoassay on a regular DVD could be implemented into the accelerated 
monitoring protocols due to the multiplex capability and the good sensitivity. However, the 
main disadvantage compared to the QCM-D sensor is that it does not give additional 
information that facilitates the full characterization of SLE patients. 
To our knowledge, the QCM-D technology is an interesting sensing approach to 
characterize SLE patients. Indeed, the developed piezoimmunosensors may be a cornerstone 
in long-term studies to monitor the stability of anti-TRIM21 and anti-TROVE2 autoantibody 
profiles over time, predicting clinical events and examining the significance of a change in 
concentration of circulating autoantibodies.  
The ideal biosensor for SLE diagnostic applications should be label-free, multiplex, 
sensitive, allowing the direct measurement of the structural interaction profile. The 
multichannel quartz crystal microbalance array with dissipation monitoring might be a good 
option that could meet the requirements to implement a biosensing tool in the routine clinical 
practice for the early detection, monitoring or management of rare diseases. 
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LEGEND OF THE FIGURES 
Figure 1.- Surface characterization of the QCM-D-based Ro biosensors: a) Scheme of the 
immobilization of the autoantigens TRIM21 and TROVE2. b) Atomic percentage measured 
by XPS, and SCA, during the protein immobilization process. c) PM–IRRAS spectra of the 
Ro SAM in the 4000–800 cm
-1
 spectral range. d) Thickness per molecule measured by DPI 
during the oriented immobilization of TROVE2 and e) TRIM21. 
Figure 2.- a) Measurement scheme of the developed piezoimmunosensor. The blue and red 
lines correspond to the frequency and dissipation factor changes monitored during the 
antigen-antibody recognition, respectively. b) Calibration curves for anti-TRIM21α and anti-
TROVE2 autoantibodies from SLE patients and healthy subjects. c) Effect of serum matrix 
on the analytical signal of the developed QCM-D sensor . 
Figure 3.- Interaction fingerprint pattern for the TRIM21α -autoantibody binding obtained 
using sera of SLE patients and healthy subjects. 
Figure 4.- a) Scheme of the microarray detection system on a standard DVD. b) Calibration 
curves for anti-TRIM21α and anti-TROVE2 circulating autoantibodies. 
 
Highlights 
An ultrasensitive superantigen piezoelectric sensor to determine circulating autoantibodies for SLE 
diagnosis and prognosis is developed. 
The sensor establishes an interaction fingerprint pattern of circulating autoantibodies, distinguishing 
clearly SLE patients from healthy donors. 
A statistical association of global disease activity with TRIM21-TROVE2 interaction was found (n = 
130 lupic patient samples, p-value = 0.0413).  
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